X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-04-22 | BHVN | Biohaven Ltd. | Bailey Gregory | Dir | P - Purchase | $41.00 | +48,780 | 1,574,568 | +3% | +$1,999,980 | ||||||
2024-04-22 | BHVN | Biohaven Ltd. | Childs John W | Dir | P - Purchase | $41.00 | +195,121 | 6,375,744 | +3% | +$7,999,961 | ||||||
2024-04-22 | BHVN | Biohaven Ltd. | Coric Vlad | CEO | P - Purchase | $41.00 | +121,951 | 3,146,085 | +4% | +$4,999,991 | ||||||
2024-04-22 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.07 | +79,000 | 119,910,407 | 0% | +$5,165 | ||||||
2024-04-18 | DAWN | Day One Biopharmaceuticals, Inc. | Blackman Samuel C. | HEAD OF R, D | S - Sale | $16.02 | -10,000 | 2,174,662 | 0% | -$160,163 | ||||||
| M | 2024-04-18 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $65.10 | -27,232 | 856,272 | -3% | -$1,772,729 | |||||
| D | 2024-04-19 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale+OE | $22.82 | -5,000 | 268,702 | -2% | -$114,123 | |||||
2024-04-19 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $24.89 | -3,361 | 225,807 | -1% | -$83,669 | ||||||
| D | 2024-04-19 | VCNX | Vaccinex, Inc. | Friedberg Albert | Dir, 10% | P - Purchase | $4.73 | +282 | 579,595 | 0% | +$1,334 | |||||
2024-04-22 | GALT | Galectin Therapeutics Inc | Freeman Kevin D | Dir | P - Purchase | $2.98 | +2,500 | 119,032 | +2% | +$7,450 | ||||||
2024-04-20 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.07 | +40,000 | 119,831,407 | 0% | +$2,798 | ||||||
2024-04-18 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale | $25.11 | -1,234 | 37,163 | -3% | -$30,986 | ||||||
2024-04-19 | HROW | Harrow, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $10.56 | +29,400 | 3,775,000 | +1% | +$310,391 | ||||||
| D | 2024-04-17 | AVTE | Aerovate Therapeutics, Inc. | Dake Benjamin T | SEE REMARKS | S - Sale+OE | $22.37 | -6,853 | 1,291 | -84% | -$153,327 | |||||
| D | 2024-04-17 | AVTE | Aerovate Therapeutics, Inc. | Gillies Hunter | CHIEF MEDICAL OFFICER | S - Sale+OE | $22.38 | -4,000 | 3,251 | -55% | -$89,522 | |||||
2024-04-17 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CEO | S - Sale | $25.14 | -787 | 67,694 | -1% | -$19,781 | ||||||
2024-04-17 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $25.14 | -1,307 | 229,168 | -1% | -$32,851 | ||||||
2024-04-18 | RARE | Ultragenyx Pharmaceutical Inc. | Crombez Eric | EVP, Chief Medical Officer | S - Sale | $44.10 | -142 | 48,785 | 0% | -$6,262 | ||||||
| DM | 2024-04-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $236.80 | -7,200 | 130 | -98% | -$1,704,990 | |||||
| D | 2024-04-18 | ME | 23Andme Holding Co. | Hibbs Kathy L | Chief Administrative Officer | S - Sale+OE | $0.47 | -38,548 | 1,252,315 | -3% | -$18,148 | |||||
| M | 2024-04-17 | CLSD | Clearside Biomedical, Inc. | Gibney Anthony S | Dir | P - Purchase | $1.30 | +100,000 | 100,000 | New | +$129,665 | |||||
| M | 2024-04-17 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.07 | +89,000 | 119,791,407 | 0% | +$5,959 | |||||
| D | 2024-04-16 | AVTE | Aerovate Therapeutics, Inc. | Noyes Timothy P | CEO | S - Sale+OE | $24.70 | -10,000 | 0 | -100% | -$246,971 | |||||
| M | 2024-04-16 | GNLX | Genelux Corp | Szalay Aladar | 10% | S - Sale | $3.59 | -71,420 | 4,113,885 | -2% | -$256,227 | |||||
| D | 2024-04-16 | ALXO | Alx Oncology Holdings Inc | Pons Jaume | Pres, CSO | S - Sale+OE | $14.20 | -50,000 | 604,205 | -8% | -$710,195 | |||||
2024-04-18 | ZTS | Zoetis Inc. | Lagano Roxanne | EVP | S - Sale | $151.17 | -923 | 15,602 | -6% | -$139,530 | ||||||
2024-04-17 | STOK | Stoke Therapeutics, Inc. | Skorpios Trust | 10% | S - Sale | $11.60 | -3,600,000 | 10,843,681 | -25% | -$41,760,000 | ||||||
| M | 2024-04-16 | CMPS | Compass Pathways Plc | Goldsmith George Jay | 10% | S - Sale | $8.61 | -69,461 | 7,949,073 | -1% | -$597,964 | |||||
| M | 2024-04-16 | CMPS | Compass Pathways Plc | Malievskaia Ekaterina | 10% | S - Sale | $8.61 | -69,461 | 7,949,073 | -1% | -$597,964 | |||||
2024-04-11 | BCEL | Atreca, Inc. | Orwin John A | Pres, CEO | P - Purchase | $0.01 | +1 | 77,542 | 0% | +$0 | ||||||
2024-04-16 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.28 | -100,000 | 12,546,116 | -1% | -$928,005 | ||||||
2024-04-16 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.28 | -100,000 | 12,546,116 | -1% | -$928,005 | ||||||
| D | 2024-04-16 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $41.60 | -4,006 | 21,271 | -16% | -$166,641 | |||||
| D | 2024-04-16 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $41.66 | -905 | 46,156 | -2% | -$37,698 | |||||
2024-04-15 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $65.56 | -37,500 | 1,813,220 | -2% | -$2,458,335 | ||||||
| D | 2024-04-15 | NUVL | Nuvalent, Inc. | Conley Emily | Dir | S - Sale+OE | $65.52 | -5,000 | 8 | -100% | -$327,607 | |||||
| D | 2024-04-15 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $44.47 | -14,375 | 27,786 | -34% | -$639,256 | |||||
2024-04-16 | RVNC | Revance Therapeutics, Inc. | Jordan Erica | Chief Commercial Officer | S - Sale | $3.80 | -2,392 | 114,864 | -2% | -$9,096 | ||||||
| M | 2024-04-15 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $65.91 | -22,768 | 883,504 | -3% | -$1,500,589 | |||||
| DM | 2024-04-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $233.73 | -7,200 | 130 | -98% | -$1,682,819 | |||||
2024-04-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $7.06 | -7,500 | 1,336,297 | -1% | -$52,924 | ||||||
| A | 2024-03-12 | ALDX | Aldeyra Therapeutics, Inc. | Machatha Stephen | Chief Development Officer | S - Sale | $3.16 | -11,537 | 252,812 | -4% | -$36,503 | |||||
| A | 2024-03-11 | ALDX | Aldeyra Therapeutics, Inc. | Greenberg Bruce | See Remarks | S - Sale | $3.41 | -13,201 | 130,154 | -9% | -$44,968 | |||||
| DM | 2024-04-12 | RCKT | Rocket Pharmaceuticals, Inc. | Southwell David P | Dir | S - Sale+OE | $24.32 | -80,000 | 114,784 | -41% | -$1,945,785 | |||||
2024-04-12 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale | $14.58 | -2,060 | 500,527 | 0% | -$30,035 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale | $14.58 | -1,525 | 213,321 | -1% | -$22,235 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale | $14.58 | -1,585 | 151,881 | -1% | -$23,109 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale | $14.58 | -3,136 | 315,045 | -1% | -$45,723 | ||||||
2024-04-12 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $14.58 | -8,360 | 2,415,247 | 0% | -$121,889 | ||||||
2024-04-09 | CLNN | Clene Inc. | General Resonance LLC | 10% | S - Sale | $0.39 | -22,500 | 15,428,212 | 0% | -$8,675 | ||||||
| DM | 2024-03-20 | PKTX | Protokinetix, Inc. | Smith Clarence Edward | Pres, CEO, 10% | P - Purchase | $0.01 | +3,166,667 | 77,137,093 | +4% | +$35,000 | |||||
| D | 2024-04-12 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $14.58 | -1,189 | 111,537 | -1% | -$17,336 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.03 | -17,500 | 394,027 | -4% | -$438,099 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Chief Scientific Officer | S - Sale+OE | $25.04 | -30,000 | 1,117,035 | -3% | -$751,332 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale+OE | $25.04 | -47,709 | 1,264,587 | -4% | -$1,194,700 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $24.72 | -14,000 | 0 | -100% | -$346,149 | |||||
| M | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $24.11 | -6,964 | 203,129 | -3% | -$167,888 | |||||
| D | 2024-04-11 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Chief Medical Officer | S - Sale+OE | $25.07 | -20,000 | 0 | -100% | -$501,478 | |||||
2024-04-12 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $67.79 | -250 | 59,731 | 0% | -$16,948 | ||||||
| D | 2024-04-11 | IRON | Disc Medicine, Inc. | White William Richard | Dir | S - Sale+OE | $31.80 | -2,560 | 0 | -100% | -$81,407 | |||||
| DM | 2024-04-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $237.19 | -7,200 | 130 | -98% | -$1,707,775 | |||||
| DM | 2024-04-11 | BMRN | Biomarin Pharmaceutical Inc | Bienaime Jean Jacques | Dir | S - Sale+OE | $91.13 | -40,000 | 722,527 | -5% | -$3,645,000 | |||||
| D | 2024-04-11 | THRD | Third Harmonic Bio, Inc. | Holles Natalie C. | CEO | S - Sale+OE | $12.19 | -13,558 | 1,218,836 | -1% | -$165,214 | |||||
2024-04-11 | ACRV | Acrivon Therapeutics, Inc. | Perceptive Advisors LLC | 10% | P - Purchase | $8.50 | +2,353,000 | 5,360,858 | +78% | +$20,000,500 | ||||||
| DM | 2024-04-10 | LGVN | Longeveron Inc. | Hare Joshua | Chief Scientific Officer, 10% | P - Purchase | $2.35 | +148,936 | 633,280 | +31% | +$350,000 | |||||
| D | 2024-04-11 | LGVN | Longeveron Inc. | Hashad Mohamed Wa'El Ahmed | CEO | P - Purchase | $2.35 | +10,638 | 19,616 | +118% | +$24,999 | |||||
| DM | 2024-04-10 | LGVN | Longeveron Inc. | Soffer Rock | Dir | P - Purchase | $2.35 | +138,298 | 208,534 | +197% | +$325,000 | |||||
| DM | 2024-04-10 | ELVN | Enliven Therapeutics, Inc. | Ballal Rahul D. | Dir | S - Sale+OE | $23.36 | -67,000 | 22,341 | -75% | -$1,564,812 | |||||
| D | 2024-04-10 | AVTE | Aerovate Therapeutics, Inc. | Eldridge George A | SEE REMARKS | S - Sale+OE | $26.85 | -7,500 | 1,960 | -79% | -$201,392 | |||||
2024-04-11 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $22.49 | -257 | 22,891 | -1% | -$5,780 | ||||||
2024-04-11 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $6.74 | -54 | 70,849 | 0% | -$364 | ||||||
2024-04-10 | VERA | Vera Therapeutics, Inc. | Young Joseph R | SVP, Finance, Chief Acct Offcr | S - Sale | $40.00 | -5,714 | 53,171 | -10% | -$228,560 | ||||||
2024-04-10 | BMRN | Biomarin Pharmaceutical Inc | Burkhart Erin | GVP, Chief Accounting Officer | S - Sale | $90.00 | -2,286 | 16,156 | -12% | -$205,740 | ||||||
| M | 2024-04-09 | BGNE | Beigene, Ltd. | Oyler John | CEO | S - Sale | $149.50 | -50,000 | 47,512,317 | 0% | -$7,475,024 | |||||
2024-04-09 | AVTE | Aerovate Therapeutics, Inc. | Grayzel David S. | Dir | S - Sale | $28.15 | -11,882 | 1,799,232 | -1% | -$334,478 | ||||||
2024-04-11 | PTN | Palatin Technologies Inc | Deveer Robert K Jr | Dir | P - Purchase | $2.12 | +6,000 | 40,845 | +17% | +$12,703 | ||||||
| DM | 2024-04-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $237.21 | -28,800 | 130 | -100% | -$6,831,737 | |||||
2024-01-02 | LIAN | Lianbio | Gu Ehong | Interim CFO | S - Sale | $4.34 | -1,731 | 0 | -100% | -$7,513 | ||||||
2024-04-10 | ATOS | Atossa Therapeutics, Inc. | Finn Jonathan | Dir | P - Purchase | $1.77 | +25,000 | 25,000 | New | +$44,250 | ||||||
| D | 2024-04-08 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Pres, R, D,, CMO | S - Sale+OE | $245.99 | -2,676 | 1,114,539 | 0% | -$658,258 | |||||
| D | 2024-04-08 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $246.19 | -26,270 | 841,275 | -3% | -$6,467,491 | |||||
2024-04-08 | RCKT | Rocket Pharmaceuticals, Inc. | White Mark Andrew | See Remarks | S - Sale | $24.64 | -12,532 | 75,226 | -14% | -$308,763 | ||||||
2024-04-08 | ONCT | Oncternal Therapeutics, Inc. | Wills Robert James | Dir | P - Purchase | $8.96 | +3,086 | 10,000 | +45% | +$27,655 | ||||||
2024-04-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $18.60 | -4,875 | 396,624 | -1% | -$90,687 | ||||||
2024-04-08 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $6.07 | +3,200 | 3,200 | New | +$19,411 | ||||||
2024-04-09 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.28 | -100,000 | 12,646,116 | -1% | -$927,735 | ||||||
2024-04-09 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.28 | -100,000 | 12,646,116 | -1% | -$927,735 | ||||||
| D | 2024-04-08 | CPRX | Catalyst Pharmaceuticals, Inc. | Tierney David S | Dir | S - Sale+OE | $15.68 | -25,000 | 348,874 | -7% | -$392,000 | |||||
2024-04-08 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $68.44 | -37,500 | 1,850,720 | -2% | -$2,566,479 | ||||||
2024-04-08 | TRDA | Entrada Therapeutics, Inc. | Kim Peter S | Dir | P - Purchase | $13.57 | +2,600 | 62,936 | +4% | +$35,290 | ||||||
2024-04-08 | PHAT | Phathom Pharmaceuticals, Inc. | Henderson Molly | CFO, CBO | S - Sale | $11.10 | -3,435 | 97,174 | -3% | -$38,129 | ||||||
| D | 2024-04-10 | AGIO | Agios Pharmaceuticals, Inc. | Fouse Jacqualyn A | Dir | S - Sale+OE | $27.55 | -7,791 | 137,396 | -5% | -$214,642 | |||||
2024-04-09 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $3.28 | +15,009 | 838,037 | +2% | +$49,230 | ||||||
| D | 2024-04-08 | ACAD | Acadia Pharmaceuticals Inc | Davis Stephen | CEO | S - Sale+OE | $17.87 | -26,574 | 144,267 | -16% | -$474,877 | |||||
| D | 2024-04-08 | ACAD | Acadia Pharmaceuticals Inc | Teehan Brendan | EVP, COO, Head of Commercial | S - Sale+OE | $17.87 | -2,568 | 38,796 | -6% | -$45,890 | |||||
| D | 2024-04-08 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $17.87 | -1,790 | 13,100 | -12% | -$31,987 | |||||
| D | 2024-04-08 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $17.87 | -2,716 | 28,742 | -9% | -$48,535 | |||||
| A | 2022-05-10 | PEPG | Pepgen Inc. | Oxford Science Enterprises Plc | 10% | P - Purchase | $12.00 | +879,970 | 4,755,388 | +23% | +$10,559,640 | |||||
| D | 2024-04-09 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $74.31 | -32,605 | 138,567 | -19% | -$2,422,918 | |||||
| DM | 2024-04-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $235.68 | -20,060 | 130 | -99% | -$4,727,736 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |